Particle.news
Download on the App Store
4 ARTICLES
·
yesterday

Monocyte-Targeted Trials Follow Validation of SIRP-Alpha Mismatch in Kidney Transplants

Validation of donor–recipient SIRP-alpha mismatch as an independent predictor of transplant outcomes offers a foundation for personalized immunosuppression research.

FILE - Surgeons work on a kidney during a transplant surgical procedure in Washington on June 28, 2016. (AP Photo/Molly Riley, File)

Overview

  • Researchers categorized the ten most prevalent human SIRP-alpha gene variants into two groups, A and B, to assess donor–recipient compatibility.
  • Analysis of 455 UPMC transplant pairs found that A/B SIRP-alpha mismatches correlated with higher acute rejection rates, accelerated fibrosis and poorer graft survival.
  • An independent cohort of 258 Northwestern University transplant pairs confirmed the link between SIRP-alpha mismatch and adverse kidney transplant outcomes.
  • The SIRP-alpha mismatch test is designed to complement existing HLA matching by improving risk stratification for potential rejection.
  • Investigators are launching clinical trials of monocyte-targeted therapies, including corticosteroids, to reduce rejection risk in SIRP-alpha-mismatched transplants.